Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 0.86 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482054 | 0.94 | ADORA3 (0.84) | ADORA3ADORA1CYP3A4 | |
| SCHEMBL6213534 | 0.93 | ADORA3 (0.86) | ADORA3ADORA1 | |
| SCHEMBL6211486 | 0.92 | ADORA3 (0.85) | ADORA3ADORA1CYP1A2CYP3A4MAPT | |
| SCHEMBL6212503 | 0.92 | ADORA3 (1.00) | ADORA3ADORA1 | |
| SCHEMBL6212935 | 0.92 | ADORA3 (0.85) | ADORA3ADORA1 | |
| SCHEMBL6217135 | 0.92 | ADORA3 (0.82) | ADORA3ADORA1 | |
| SCHEMBL6217610 | 0.92 | ADORA3 (0.84) | ADORA3ADORA1CYP1A2CYP3A4MAPT | |
| SCHEMBL6212725 | 0.91 | ADORA3 (0.82) | ADORA3ADORA1CYP1A2CYP3A4MAPT | |
| SCHEMBL6215767 | 0.91 | ADORA3 (0.82) | ADORA3ADORA1CYP1A2CYP3A4MAPT | |
| SCHEMBL6217410 | 0.88 | ADORA3 (0.91) | ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216257-B1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6803457-B1 | ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | ADORA3 26/4885ADORA1 227/4885CYP1A2 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.